object
unclear
whether
patient
hypertens
like
infect
gener
popul
whether
differ
sever
pneumonia
patient
taken
aceiarb
drug
lower
blood
pressur
compar
method
observ
studi
includ
data
patient
clinic
confirm
admit
hankou
hospit
wuhan
china
januari
march
data
extract
clinic
laboratori
record
followup
cutoff
march
result
total
patient
hypertens
without
hypertens
includ
analysi
patient
hypertens
older
like
preexist
comorbid
includ
chronic
renal
insuffici
cardiovascular
diseas
diabet
mellitu
cerebrovascular
diseas
patient
without
hypertens
moreov
patient
hypertens
tend
higher
posit
pcr
detect
rate
patient
hypertens
previous
taken
aceiarb
drug
antihypertens
treatment
increas
tendenc
develop
sever
pneumonia
infect
p
conclus
patient
hypertens
significantli
older
like
underli
comorbid
includ
chronic
renal
insuffici
cardiovascular
diseas
diabet
mellitu
cerebrovascular
diseas
patient
hypertens
taken
aceiarb
drug
antihypertens
treatment
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
increas
tendenc
develop
sever
pneumonia
infect
futur
studi
larger
sampl
size
multicent
clinic
data
need
support
conclus
decemb
cluster
sever
case
pneumonia
unknown
caus
emerg
wuhan
china
clinic
present
greatli
resembl
viral
pneumonia
deep
sequenc
analysi
lower
respiratori
tract
sampl
indic
novel
coronaviru
name
coronaviru
diseas
mar
hypertens
rate
rang
nonsever
patient
sever
patient
total
incid
high
interestingli
angiotensinconvert
enzym
involv
pathogenesi
hypertens
pneumonia
reason
prompt
us
specul
organ
attack
might
lung
may
also
includ
express
organ
especi
cardiovascular
system
addit
patient
comorbid
hypertens
especi
longterm
oral
aceiarb
medic
hypertens
might
differ
suscept
sever
level
pneumonia
upon
infect
therefor
investig
compar
demograph
characterist
coexist
diseas
sever
pneumonia
effect
antihypertens
drug
aceiarb
versu
nonaceiarb
patient
coexist
hypertens
find
may
hope
reduc
mortal
morbid
associ
hypertens
patient
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
singlecent
retrospect
observ
studi
conduct
hankou
hospit
one
hospit
design
treat
pneumonia
patient
wuhan
china
criteria
suspect
confirm
case
base
criteria
previous
establish
patient
met
criteria
includ
studi
patient
year
whose
entir
stay
hospit
last
hour
exclud
analysi
studi
approv
nation
health
commiss
china
ethic
commiss
hankou
hospit
ethic
commiss
hankou
hospit
waiv
requir
obtain
inform
consent
obtain
epidemiolog
demograph
clinic
laboratori
manag
outcom
data
patient
medic
record
use
standard
data
collect
form
clinic
outcom
follow
march
analyz
relationship
stage
hypertens
clinic
outcom
minimum
followup
time
day
requir
includ
followup
patient
discharg
march
data
miss
record
clarif
need
research
also
directli
commun
patient
famili
ascertain
epidemiolog
symptom
data
data
check
two
physician
ts
hh
initi
investig
includ
complet
blood
count
coagul
profil
serum
biochem
test
includ
renal
liver
function
creatin
kinas
lactat
dehydrogenas
ldh
electrolyt
common
respiratori
pathogen
descript
treatment
procedur
measur
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
publish
previous
definit
classif
hypertens
obtain
previous
publish
literatur
definit
sever
nonsever
pneumonia
obtain
publish
literatur
patient
receiv
chest
comput
tomographi
ct
scan
admiss
ct
imag
review
two
fellowshiptrain
cardiothorac
radiologist
gx
fw
approxim
year
experi
use
electron
medic
record
system
hankou
hospit
imag
review
independ
final
decis
reach
consensu
case
disagr
two
primari
radiologist
interpret
third
fellowshiptrain
cardiothorac
radiologist
year
experi
hl
adjud
final
decis
neg
control
case
examin
blind
occur
radiologist
evalu
initi
ct
scan
assign
quantit
score
characterist
use
recent
publish
score
system
total
ct
score
sum
lung
involv
lobe
score
lobe
rang
none
maximum
primari
variabl
interest
mortal
calcul
day
admiss
secondari
outcom
variabl
includ
sever
pneumonia
length
hospit
stay
discharg
rate
hospit
hospit
rate
studi
approv
nation
health
commiss
china
ethic
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
commiss
hankou
hospit
ethic
commiss
hankou
hospit
waiv
requir
obtain
inform
consent
statist
analysi
perform
use
spss
softwar
window
version
ibm
corp
armonk
ny
usa
descript
analys
perform
demograph
clinic
laboratori
data
bivari
analys
use
assess
associ
hypertens
statu
differ
paramet
interest
continu
data
white
blood
cell
count
convert
categor
variabl
normal
low
high
level
multivari
analysi
perform
due
small
sampl
size
odd
ratio
obtain
logist
regress
use
measur
strength
associ
factor
hypertens
p
valu
consid
indic
statist
signific
date
symptom
onset
use
start
date
conduct
death
certif
search
medic
record
determin
whether
patient
aliv
discharg
die
subsequ
includ
data
analysi
applic
studi
period
total
patient
admit
met
case
definit
clinic
confirm
inclus
criteria
characterist
patient
admiss
overal
accord
hypertens
statu
shown
tabl
patient
hypertens
patient
without
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
hypertens
compar
patient
without
hypertens
patient
hypertens
significantli
older
like
underli
comorbid
includ
chronic
renal
insuffici
cardiovascular
diseas
diabet
mellitu
cerebrovascular
diseas
patient
hypertens
tend
longer
time
onset
admiss
higher
posit
pcr
detect
rate
tabl
show
result
laboratori
test
perform
admiss
accord
hypertens
statu
patient
hypertens
higher
level
serum
creatinin
scr
lower
level
hemoglobin
ddimer
whole
blood
patient
without
hypertens
differ
clinic
outcom
found
patient
hypertens
without
hypertens
tabl
compar
characterist
clinic
outcom
patient
histori
hypertens
previous
taken
aceiarb
drug
case
sever
pneumonia
seen
among
patient
taken
aceiarb
drug
patient
even
though
taken
aceiarb
drug
younger
age
p
pneumonia
sever
statu
admiss
p
signific
differ
index
found
two
group
tabl
observ
show
patient
hypertens
previous
taken
aceiarb
drug
antihypertens
treatment
increas
tendenc
develop
sever
pneumonia
infect
hypertens
patient
may
need
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
adjust
medic
elimin
aceiarb
drug
reduc
risk
sever
pneumonia
mechanist
increas
zinc
metallopeptidas
might
help
enter
cell
acceler
replic
known
human
homologu
key
regul
blood
pressur
angiotensinconvert
enzym
ace
sinc
discoveri
implic
play
import
role
preserv
heart
function
balanc
blood
pressur
effect
mediat
part
abil
convert
angiotensin
ii
ang
ii
angiotensin
unexpectedli
also
serv
cellular
entri
point
sever
acut
respiratori
syndrom
sar
viru
enzym
therefor
prime
target
pharmacolog
intervent
coronavirusrel
diseas
identifi
receptor
sever
acut
respiratori
syndrom
coronaviru
sarscov
mediat
infect
transmiss
sarscov
effect
reli
proteas
activ
ace
structur
analysi
show
spinou
protein
sarscov
contact
headend
catalyt
domain
subunit
involv
subunit
ii
block
activ
region
sarscov
connect
extracellular
part
lyse
transmembran
part
transfer
cell
mediat
fusion
viru
particl
host
cell
nextgener
sequenc
technolog
entir
genom
sequenc
success
determin
compar
genom
sequenc
previou
coronavirus
found
similar
sarscov
worth
note
aceiarb
drug
administ
hypertens
patient
result
increas
express
lung
role
opposit
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ace
hydrolyz
angiotensin
ang
produc
angiotensin
peptid
therebi
gener
vasodil
lower
blood
pressur
aceiarb
drug
may
increas
protein
concentr
rat
plasma
mrna
level
even
activ
cardiac
tissu
thu
possibl
hypertens
patient
take
aceiarb
might
increas
level
mrna
protein
express
lung
make
vulner
entri
well
develop
sever
pneumonia
find
worth
investig
howev
scholar
believ
downregul
express
neo
coronaviru
challeng
aggrav
lung
injuri
opinion
mainli
come
anim
model
studi
multipl
laboratori
small
sampl
clinic
studi
studi
shown
express
decreas
viral
infect
caus
acut
lung
injuri
exogen
supplement
could
allevi
acut
lung
injuri
human
recombin
ace
angiotensin
ii
type
receptor
protect
mice
sever
acut
lung
injuri
induc
acid
aspir
sepsi
found
patient
acut
respiratori
distress
syndrom
ard
treat
inject
rapidli
decreas
level
ang
ii
increas
level
downregul
caus
imbal
aceang
ii
activ
ang
ii
reninangiotensinaldosteron
system
raa
enhanc
lack
antagon
ang
ii
mediat
increas
pulmonari
vascular
permeabl
bind
receptor
might
also
caus
pulmonari
vascular
contract
result
hydrostat
pressur
elev
pulmonari
edema
clinic
evid
requir
determin
whether
express
downregul
human
coronaviru
includ
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
nevertheless
result
studi
suggest
widespread
pandem
hypertens
popul
may
need
quickli
consid
choic
antihypertens
medic
reduc
possibl
develop
sever
pneumonia
investig
found
patient
take
aceiarb
agent
younger
patient
take
nonaceiarb
agent
may
relat
doctor
prescrib
habit
howev
directli
conclud
patient
take
aceiarb
antihypertens
drug
sever
pneumonia
take
aceiarb
drug
mani
confound
factor
coexist
diseas
yet
exclud
survey
show
popul
hypertens
seem
suscept
compar
nonhypertens
popul
previous
larg
sampl
studi
patient
show
hypertens
coexist
diseas
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
research
follow
limit
first
survey
focus
hankou
hospit
wuhan
number
patient
includ
small
larger
sampl
size
multicent
clinic
data
need
support
conclus
futur
studi
second
investig
includ
clinic
confirm
case
mani
patient
test
lack
nucleic
acid
test
kit
begin
outbreak
patient
suspect
exclud
studi
test
neg
hospit
howev
base
exact
epidemiolog
histori
patient
sign
symptom
chest
ct
examin
result
trust
reliabl
diagnosi
patient
third
due
urgent
data
collect
shorter
followup
time
patient
shortest
hospit
stay
patient
day
may
interfer
final
prognosi
lead
failur
analyz
surviv
time
fourth
analyz
comorbid
shock
ard
focu
analyz
risk
associ
hypertens
provid
evid
issu
prevent
treatment
guidelin
patient
coexist
hypertens
significantli
older
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
like
underli
comorbid
includ
chronic
renal
insuffici
cardiovascular
diseas
diabet
mellitu
cerebrovascular
diseas
patient
hypertens
tend
longer
time
onset
admiss
higher
posit
pcr
detect
rate
patient
hypertens
taken
aceiarb
drug
antihypertens
treatment
increas
tendenc
develop
sever
pneumonia
infect
futur
studi
larger
sampl
size
multicent
clinic
data
need
support
conclus
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
bai
c
gao
song
j
xia
p
dong
j
zhao
j
wang
fs
patholog
find
associ
acut
respiratori
distress
syndrom
lancet
respir
med
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
onset
admiss
day
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
data
present
n
mean
sd
median
iqr
p
valu
compar
hypertens
nonhypertens
patient
na
applic
novel
coronaviru
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
